Latest filing published 17 Apr 2019 for ALNYLAM PHARMACEUTICALS, INC., €293k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +224.2%Entry US$25.00 · Close at T+365 US$81.05
- +69.4%Entry US$13.58 · Close at T+365 US$23.01
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Philip A. Sharp: trading record in brief
Philip A. Sharp is a declared insider at 3 companies; the most frequent names are Biogen Inc., Alnylam Pharmaceuticals, Inc. and Syros Pharmaceuticals, Inc. Over a trading history stretching from 25 May 2007 to 15 April 2019, the count stands at 125 filings.
The open-market side counts 2 purchases for €151k alongside 84 sales for €24.1M. Netting one side against the other leaves €23.9M of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 3 share grants and 14 option exercises. 2019 to date brings no purchases and 4 sales.
Most recently, on 17 April 2019, the filings show an open-market sale worth €49k in Alnylam Pharmaceuticals, Inc. The most recent open-market purchase was published on 24 January 2013, 5,036 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Philip A. Sharp
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 15,000 shares@ US$22.0920.0% of flowCommon StockSEC:0001735276-19-000037:0
- 11,800 shares@ US$87.8662.7% of flowCommon StockSEC:0001735276-19-000037:1
- 2,200 shares@ US$89.0311.8% of flowCommon StockSEC:0001735276-19-000037:2
- 400 shares@ US$89.972.2% of flowCommon StockSEC:0001735276-19-000037:3
- 600 shares@ US$91.403.3% of flowCommon StockSEC:0001735276-19-000037:4
- 15,000 shares@ US$21.352.9% of flowCommon StockSEC:0001553878-18-000021:0
- 15,000 shares@ US$149.0020.6% of flowCommon StockSEC:0001553878-18-000021:1
- 15,000 shares@ US$27.283.8% of flowCommon StockSEC:0001325812-18-000020:0
- 15,000 shares@ US$129.0017.9% of flowCommon StockSEC:0001325812-18-000020:1
- 25,000 shares@ US$31.298.2% of flowCommon StockSEC:0001553878-17-000009:0
- 4,829 shares@ US$40.162.0% of flowCommon StockSEC:0001553878-17-000009:2
- 20,171 shares@ US$39.728.4% of flowCommon StockSEC:0001553878-17-000009:1
- 15,000 shares@ US$31.395.0% of flowCommon StockSEC:0001553878-17-000007:0
- 15,000 shares@ US$37.956.0% of flowCommon StockSEC:0001553878-17-000007:1
- 15,000 shares@ US$15.912.5% of flowCommon StockSEC:0001553878-17-000004:0
- 8,800 shares@ US$37.573.5% of flowCommon StockSEC:0001553878-17-000004:1
- 6,200 shares@ US$38.202.5% of flowCommon StockSEC:0001553878-17-000004:2
- 146,666 sharesCommon StockSEC:0001104659-16-131386:0
- 40,000 sharesCommon StockSEC:0001104659-16-131386:1
- 40,000 sharesCommon StockSEC:0001104659-16-131386:2
- 40,000 sharesCommon StockSEC:0001104659-16-131386:3
- 10,000 shares@ US$14.74Common StockSEC:0001553878-15-000034:0
- 20,000 shares@ US$14.05Common StockSEC:0001553878-15-000034:1
- 30,000 shares@ US$109.00Common StockSEC:0001553878-15-000034:2
- 25,844 shares0Common StockSEC:0001325812-15-000044:0
25 of 124 declarations
